Cardiac 123I-Meta-Iodobenzylguanidine Imaging as a Biomarker for Body-First Parkinson’s Disease: Linking Peripheral α-Synuclein to Clinical Subtyping
Journal of Movement Disorders · 31.01.2026 · 19 (1) · 1-10
DOI: 10.14802/jmd.25137 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Movement Disorders, erschienen am 31.01.2026. Verfasst von Dong-Woo Ryu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, College of Medicine, The Catholic University of Korea, Seoul, Korea. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Science and ICT.
Abstract (Originalsprache)
Recent neuropathological and imaging studies support the concept of “brain-first vs. body-first” Parkinson’s disease (PD), which is based on the α-synuclein origin site and connectome model. The body-first phenotype is characterized by early involvement of the peripheral autonomic nervous system, particularly the cardiac sympathetic nerves and enteric nerves. 123I-meta-iodobenzylguanidine (123I-MIBG) myocardial scintigraphy is a well-established method for evaluating cardiac sympathetic innervation. This review explores the potential of 123I-MIBG scintigraphy as a biomarker to differentiate the body-first phenotype from the brain-first phenotype. Reduced 123I-MIBG uptake has been observed in idiopathic rapid eye movement (REM) sleep behavior disorder, pure autonomic failure, and incidental Lewy body disease—conditions strongly associated with prodromal or early-stage PD. Postmortem and biopsy evidence indicates α-synuclein accumulation in cardiac nerves and other peripheral sites, which is consistent with bottom-up progression. α-Synuclein seed amplification assays further corroborate the association between the peripheral α-synuclein burden and reduced 123I-MIBG uptake. While 123I-MIBG myocardial scintigraphy is a promising tool, its limitations include cost, limited availability, and potential confounding from underlying cardiac conditions. Nonetheless, early detection of cardiac sympathetic denervation via 123I-MIBG imaging may enhance diagnosis, support subtype classification, and improve the understanding of PD pathogenesis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Förderung
- National Research Foundation of Korea
- Ministry of Science and ICT
Zitieren
APA
Ryu, D. W., Yoo, S. W., Oh, Y., & Kim, J. S. (2026). Cardiac 123I-Meta-Iodobenzylguanidine Imaging as a Biomarker for Body-First Parkinson’s Disease: Linking Peripheral α-Synuclein to Clinical Subtyping. Journal of Movement Disorders, 19(1), 1-10. https://doi.org/10.14802/jmd.25137
Vancouver
Ryu DW, Yoo SW, Oh Y, Kim JS. Cardiac 123I-Meta-Iodobenzylguanidine Imaging as a Biomarker for Body-First Parkinson’s Disease: Linking Peripheral α-Synuclein to Clinical Subtyping. Journal of Movement Disorders. 2026;19(1):1-10. doi:10.14802/jmd.25137
BibTeX
@article{Ryu2026,
author = {Ryu, Dong-Woo and Yoo, Sang-Won and Oh, Yoonsang and Kim, Joong-Seok},
title = {Cardiac 123I-Meta-Iodobenzylguanidine Imaging as a Biomarker for Body-First Parkinson’s Disease: Linking Peripheral α-Synuclein to Clinical Subtyping},
journal = {Journal of Movement Disorders},
year = {2026},
volume = {19},
number = {1},
pages = {1--10},
doi = {10.14802/jmd.25137}
}
EUVIMED